Trial Profile

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Cabozantinib (Primary) ; Capecitabine (Primary) ; Daratumumab (Primary) ; Enzalutamide (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Nivolumab/relatlimab (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Regorafenib (Primary) ; Relatlimab (Primary) ; Rucaparib (Primary) ; Sunitinib (Primary) ; Temozolomide (Primary) ; Trametinib (Primary)
Indications Cancer
Focus Adverse reactions
Acronyms CheckMate 8TT
Sponsors Bristol-Myers Squibb

25 Apr 2024 This trial has been completed in Hungary.
24 Apr 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
09 Apr 2024 Planned number of patients changed from 1231 to 1500.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com